What is RedDrop Dx?
RedDrop Dx operates at the intersection of medical device engineering and diagnostic infrastructure. The company has developed the RedDrop ONE, an FDA-cleared blood lancet device designed to facilitate clinical-grade capillary blood collection without the necessity of a phlebotomist. By enabling individuals to collect samples directly into automation-compatible tubes, RedDrop Dx eliminates the logistical bottlenecks typically associated with remote diagnostics. This innovation allows clinical laboratories to integrate remote samples into existing high-throughput workflows without requiring costly redesigns or specialized processing equipment, positioning the company as a critical enabler of the modern, decentralized healthcare ecosystem.
How much funding has RedDrop Dx raised?
RedDrop Dx has raised a total of $5M across 1 funding round:
Seed
$5M
Seed (2025): $5M with participation from Breakthrough Ventures, Innosphere Ventures, and Stout Street Capital
Key Investors in RedDrop Dx
Breakthrough Ventures
Breakthrough Venture Capital is a Wyoming-based early-stage investment fund that partners with high-growth startups in the Mountain West region, focusing on Seed to Series A companies.
Innosphere Ventures
Innosphere Ventures is a non-profit organization that accelerates science and technology-based startups through specialized accelerator programs, laboratory facilities, and venture capital.
Stout Street Capital
Stout Street Capital is a Denver-based venture capital firm specializing in early-stage technology companies, with a focus on post-product, post-revenue B2B SaaS and advanced technology startups.
What's next for RedDrop Dx?
With the recent strategic investment, RedDrop Dx is poised to accelerate its market penetration and operational scaling. The company's roadmap likely involves expanding its distribution channels to reach a wider array of clinical laboratories and diagnostic service providers. By leveraging the expertise of its investor base, RedDrop Dx will focus on optimizing its manufacturing capabilities to meet the anticipated demand for its blood collection devices. Furthermore, the company is expected to continue refining its diagnostic infrastructure, potentially exploring new partnerships that integrate its collection technology into broader telehealth and remote monitoring platforms. As the healthcare industry continues to prioritize patient-centric care, RedDrop Dx is strategically positioned to become the standard for scalable, remote blood diagnostics.
See full RedDrop Dx company page
